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Materials and methods 
Flow cytometry 
To examine mouse erythropoiesis, FITC-conjugated anti-Gr1 antibody (BioLegend, 108405) and 
anti-CD11b antibody (BD, 553310), PECy7-conjugated anti-B220 antibody (BioLegend, 
103221) and anti-CD3 antibody (BioLegend, 100319), PE-conjugated anti-CD71 antibody (BD, 
553267) and APC-conjugated anti-Ter119 antibody (BioLegend, 116212) were used. Different 
erythroid progenitor populations were discriminated based on CD71 and Ter119 expression in 
combination with cell size (FSC) as described before. To analyze the cell cycle of erythroid 
progenitors, cells were first stained with the antibodies listed above, fixed and permeabilized 
using FITC BrdU Flow Kit (BD, 51-2354AK) and stained with DAPI. Stained cells were 
analyzed using LSRII (BD) and data were analyzed using FlowJo software. 
Transduced CB CD34
+
 cells were sorted for green fluorescence (GFP) and CD34 
expression after staining with an allophycocyanin (APC)–conjugated anti-CD34 antibody (BD 
Biosciences PharMingen), using a fluorescence-activated cell sorting (FACS) Vantage cell 
sorter. To examine Epo-induced erythropoiesis of human cord blood CD34
+
 cells, APC-
conjugated anti-human CD71 antibody (BioLegend, 334107) and PE-conjugated anti-human 
Glycophorin A antibody (eBioscience, 12-9987-80) were used. 
Blood cell counts 
Mouse peripheral blood was collected from tail vein in EDTA-treated tubes and analyzed on a 
Hemavet machine (Drew Scientific). 
Purification and in vitro primary culture of human CB CD34
+
 cells 
 
 
Mononuclear cells were isolated from CB (obtained from the Indiana University Hospital on a 
contractual basis) by Ficoll-Hypaque Plus density centrifugation. CD34
+
 HSPCs were purified 
by positive selection using the Midi-magnetic-activated cell sorting LS
+
 separation columns and 
isolation kit (Miltenyi). CD34
+
 cells were expanded for 3 days in StemSpan SFEM (StemCell 
Technologies) supplemented with stem cell factor (SCF; 100 ng/mL), Flt3 ligand (Flt3L; 10 
ng/mL) and thrombopoietin (TPO; 100 ng/mL; these cytokines were purchased from 
PeproTech). 
CD34
+
 cells were cultured in StemSpan SFEM (StemCell Technologies), with different 
cytokines to support erythroid differentiation. The erythroid cultures contained Epo (6 IU/mL) 
and SCF (100 ng/mL). Epo was purchased from Amgen, and the other cytokines were purchased 
from PeproTech.  
RNA extraction and quantitative real-time RT-PCR 
For quantitative reverse-transcription polymerase chain reaction (RT-PCR), total RNA was 
isolated using the RNeasy Plus Micro Kit (QIAGEN), and then subjected to reverse transcription 
with random hexamers (SuperScript III kit; Invitrogen). Quantitative real-time PCR was 
performed with SYBR Green (Qiagen) on an ABI PRISM 7500 system. Gene specific primers 
were designed to flank introns so that products from cDNA could be distinguished from possible 
genomic DNA contamination. Primer sequences are available upon request. 
 
 
SUPPLEMENTARY FIGURE LEGENDS  
Figure S1. (A) Equal number of bone marrow mononuclear cells from WT and Bmi1 null mice 
were plated on methylcellulose medium. GEMM, GM and BFU-E colonies were counted on day 
9-10. Data are means ± SD, n=3, *p<0.05; ***p<0.001. (B) CMP, GMP and MEP frequencies in 
WT and Bmi1 null bone marrow cells were quantified by flow cytometric analysis. Data are 
means ± SD, n=6. 
Figure S2. Human cord blood CD34
+
 cells were transduced with lentiviruses. The percent of 
GFP
+ 
cells reflects transduction efficiency. 
Figure S3. Expression of CD71 and GlyA on human HSPCs, cultured with different 
concentrations of EPO, as assayed by flow cytometric analysis at Days 3, 5 and 7. 
Figure S4. (A) Transcript profiling of MEPs from WT and Bmi1
-/-
 mice were analyzed by 
Agilent Whole Mouse Genome Oligo Microarrays. Genes whose expressions are increased or 
decreased more than 2-fold in Bmi1
-/-
 MEPs compared to wild-type cells are shown. Data shown 
are relative expression as compared to WT MEPs (set as 1). We utilized Ingenuity pathways 
Analysis (Ingenuity Systems) to group genes into specific canonical pathways. Values are shown 
for three biological replicates. (B) Real time RT-PCR analysis of ribosomal protein gene 
expression in immature erythroid progenitor cells (CD71
-
Ter119
-
) from WT and Bmi1
-/-
 mice. 
Data shown are relative expression as compared to WT MEPs (set as 1). Data are means ± SD. 
Value are shown for three biological replicates. 
Figure S5. Lentiviral constructs expressing shRNAs targeting luciferase (control) or BMI1 led to 
efficient knockdown of BMI1 expression in human K562 cells, as assessed by quantitative RT-
PCR (A) and Western blot (B). 
 
 
Figure S6. Chromatin-bound DNA from K562 cells were immunoprecipitated with a BMI1-
antibody, a RING1B-antibody or with normal mouse IgG. qPCR amplification was performed on 
corresponding templates using primers for RPS14, RPL5, RPL11 and RPL23 genes. 
Figure S7. Chromatin-bound DNA from K562 cells were immunoprecipitated with a H3K4me3-
-antibody, a H3K9ac-antibody, a H3K27me3-antibody, or with normal mouse IgG. qPCR 
amplification was performed on corresponding templates using primers for RPS14, RPL5, 
RPL11 and RPL23 genes. 
Figure S8. Chromatin-bound DNA from K562 cells were immunoprecipitated with a 
H2AK119Ub1-antibody or with normal mouse IgG. qPCR amplification was performed on 
corresponding templates using primers for RPS19 gene. 
Figure S9. p19
Arf 
expression in Bmi1 null pro-E cells (A) and in BMI1 KD CD34
+
 cells (B) was 
assessed by quantitative RT-PCR analysis. Data are means ± SD. Value are shown for three 
biological replicates. *p<0.05; ***p<0.001. 
Figure S10. Cell cycle analysis of CD71
-
Ter119
- 
cells from the bone marrow of WT and Bmi1 
null mice. Data are means ± SD, *p<0.05, n=3.  
Figure S11. Myeloid differentiation of bone marrow mononuclear cells from WT, Bmi1
-/-
 and 
Bmi1
-/-
p53
R248W
 mice was assayed by flow cytometry. Data are means ± SD, n=3, **p<0.01; 
***p<0.001. 
Figure S12. (A) Real time RT-PCR analysis of Bmi1 and p21 expression in proerythroblasts 
(CD71
high
Ter119
low
) from the bone marrow of WT, Bmi1
-/-
 and Bmi1
-/-
p53
R248W
 mice. Data 
shown are relative expression as compared to WT cells (set as 1). Data are means ± SD. Value 
 
 
are shown for three biological replicates. ***p<0.001. (B) Cell cycle analysis of proerythroblasts 
(CD71
high
Ter119
low
) from the bone marrow of WT, Bmi1
-/-
 and Bmi1
-/-
p53
R248W
 mice.  
Figure S13. Real time RT-PCR analysis of ribosomal protein gene expression in CD71
-
 Ter119
-
 
cells from WT, Bmi1
-/-
 and Bmi1
-/-
p53
R248W
 mice. Data shown are relative expression as 
compared to WT cells (set as 1). Data are means ± SD. Value are shown for three biological 
replicates. *p<0.05; **p<0.01;***p<0.001. 
Figure S14. Body weight of 10 to 12 weeks old mice with indicated genotype is shown. n=3-8 
mice per group, **p<0.01.   
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